Isabelle Choi
Memorial Sloan Kettering Cancer Center · Proton Collaborative Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Isabelle Choi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:02 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07918989 · A Study of Different Skin Care Approaches to Prevent Skin Reactions in People With Breast Cancer Receiving Radiation Therapy After MastectomyMemorial Sloan Kettering Cancer Center · recruiting · Breast Cancer, Breast Cancer Female · principal investigator
- Ph3NCT05856773 · Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton TherapyProton Collaborative Group · recruiting · Breast Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:02 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- 18 citationsRCR 0.8
- Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16).Eur J Cancer · 202314 citationsRCR 1.0
- 7 citationsRCR 3.5
- Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.Cancer Immunol Immunother · 20246 citationsRCR 0.5
- Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer.Clin Cancer Res · 20255 citationsRCR 0.8
- Clinical impacts of tumor cell contamination of hematopoietic stem cell products in metastatic breast cancer patients undergoing autologous peripheral blood stem cell transplantation: multicenter trial.J Korean Med Sci · 20011 citationsRCR 0.0
- Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy.Invest New Drugs · 20091 citationsRCR 0.0